Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Photoimmunotheranostic agents for triple-negative breast cancer diagnosis and therapy that can be activated on demand.
Amoury M, Bauerschlag D, Zeppernick F, von Felbert V, Berges N, Di Fiore S, Mintert I, Bleilevens A, Maass N, Bräutigam K, Meinhold-Heerlein I, Stickeler E, Barth S, Fischer R, Hussain AF. Amoury M, et al. Among authors: stickeler e. Oncotarget. 2016 Aug 23;7(34):54925-54936. doi: 10.18632/oncotarget.10705. Oncotarget. 2016. PMID: 27448975 Free PMC article.
An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
Meinhold-Heerlein I, Bauerschlag D, Zhou Y, Sapinoso LM, Ching K, Frierson H Jr, Bräutigam K, Sehouli J, Stickeler E, Könsgen D, Hilpert F, von Kaisenberg CS, Pfisterer J, Bauknecht T, Jonat W, Arnold N, Hampton GM. Meinhold-Heerlein I, et al. Among authors: stickeler e. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):458-66. doi: 10.1158/1078-0432.CCR-06-0691. Clin Cancer Res. 2007. PMID: 17255266
Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.
Schmidt G, Gerlinger C, Juhasz-Böss I, Stickeler E, Rody A, Liedtke C, Wimberger P, Link T, Müller E, Fehm T, Abel M, Stein S, Bohle R, Endrikat J, Solomayer EF. Schmidt G, et al. Among authors: stickeler e. J Cancer Res Clin Oncol. 2016 Jun;142(6):1369-76. doi: 10.1007/s00432-016-2146-z. Epub 2016 Mar 23. J Cancer Res Clin Oncol. 2016. PMID: 27008006
ERN1 and ALPK1 inhibit differentiation of bi-potential tumor-initiating cells in human breast cancer.
Strietz J, Stepputtis SS, Preca BT, Vannier C, Kim MM, Castro DJ, Au Q, Boerries M, Busch H, Aza-Blanc P, Heynen-Genel S, Bronsert P, Kuster B, Stickeler E, Brabletz T, Oshima RG, Maurer J. Strietz J, et al. Among authors: stickeler e. Oncotarget. 2016 Dec 13;7(50):83278-83293. doi: 10.18632/oncotarget.13086. Oncotarget. 2016. PMID: 27829216 Free PMC article.
Detection and Specific Elimination of EGFR+ Ovarian Cancer Cells Using a Near Infrared Photoimmunotheranostic Approach.
Bauerschlag D, Meinhold-Heerlein I, Maass N, Bleilevens A, Bräutigam K, Al Rawashdeh W, Di Fiore S, Haugg AM, Gremse F, Steitz J, Fischer R, Stickeler E, Barth S, Hussain AF. Bauerschlag D, et al. Among authors: stickeler e. Pharm Res. 2017 Apr;34(4):696-703. doi: 10.1007/s11095-017-2096-4. Epub 2017 Jan 10. Pharm Res. 2017. PMID: 28074431
Fine Tuning Antibody Conjugation Methods using SNAP-tag Technology.
Chouman K, Woitok M, Mladenov R, Kessler C, Weinhold E, Hanz G, Fischer R, Meinhold-Heerlein I, Bleilevens A, Gresch G, Haugg AM, Zeppernick F, Bauerschlag D, Maass N, Stickeler E, Kolberg K, Hussain AF. Chouman K, et al. Among authors: stickeler e. Anticancer Agents Med Chem. 2017;17(10):1434-1440. doi: 10.2174/1871520617666170213123737. Anticancer Agents Med Chem. 2017. PMID: 28270070
Simultaneous and Independent Dual Site-Specific Self-Labeling of Recombinant Antibodies.
Wollschlaeger C, Meinhold-Heerlein I, Cong X, Bräutigam K, Di Fiore S, Zeppernick F, Klockenbring T, Stickeler E, Barth S, Hussain AF. Wollschlaeger C, et al. Among authors: stickeler e. Bioconjug Chem. 2018 Nov 21;29(11):3586-3594. doi: 10.1021/acs.bioconjchem.8b00545. Epub 2018 Oct 17. Bioconjug Chem. 2018. PMID: 30289242
238 results